person · Reporting owner

Iannone Robert

Disclosed activity across 6 companies

Tapewire entity: 18427
SEC CIK: 0001737329

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Autolus Therapeutics plcAUTL · Entity 1933	Director	June 29, 2026	July 01, 2026
IMMUNOMEDICS INCIMMU · Entity 145732	CHIEF MEDICAL OFFICER	March 14, 2019	March 18, 2019
Jazz Pharmaceuticals plcJAZZ · Entity 818	EVP, Global Head of R&D & CMO	August 27, 2026	August 31, 2026
PLIANT THERAPEUTICS, INC.PLRX · Entity 7022	Director	July 09, 2026	July 13, 2026
iTeos Therapeutics, Inc.ITOS · Entity 75965	Director	June 11, 2024	June 13, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Autolus Therapeutics plc

Report date June 29, 2026 · Filed July 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	31,667	Reported balance After 2026-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29	Direct	47,500	Reported balance After 2026-06-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

F2: The RSUs vest in one installment on June 29, 2027.

F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

IMMUNOMEDICS INC

Report date March 14, 2019 · Filed March 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2026-03-14	Direct	51,230	Reported balance After 2019-03-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-03-14 · Grant · Acquired 51,230 · Balance 51,230 F1: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2026-03-14	Direct	25,660	Reported balance After 2019-03-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-03-14 · Grant · Acquired 25,660 · Balance 25,660 F2: The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.

F2: The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.

Jazz Pharmaceuticals plc

Report date August 27, 2026 · Filed August 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	65,686	Ending reported balance After 2026-08-27 transaction · row 10 10 source rows · reconciled sequence Row 1 · 2026-08-27 · Exercise / conversion · Acquired 26,116 · Balance 111,223 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 2 · 2026-08-27 · Exercise / conversion · Acquired 884 · Balance 112,107 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 3 · 2026-08-27 · Exercise / conversion · Acquired 27,584 · Balance 139,691 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 4 · 2026-08-27 · Exercise / conversion · Acquired 2,916 · Balance 142,607 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 5 · 2026-08-27 · Sale · Disposed 18,187 · Balance 124,420 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 6 · 2026-08-27 · Sale · Disposed 11,423 · Balance 112,997 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 7 · 2026-08-27 · Sale · Disposed 18,113 · Balance 94,884 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 8 · 2026-08-27 · Sale · Disposed 19,639 · Balance 75,245 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F5: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 9 · 2026-08-27 · Sale · Disposed 9,259 · Balance 65,986 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 10 · 2026-08-27 · Sale · Disposed 300 · Balance 65,686 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.10 · Expires 2030-02-26	Direct	0	Reported balance After 2026-08-27 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-08-27 · Exercise / conversion · Disposed 884 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.12 · Expires 2029-08-07	Direct	0	Reported balance After 2026-08-27 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-08-27 · Exercise / conversion · Disposed 2,916 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.10 · Expires 2030-02-26	Direct	0	Reported balance After 2026-08-27 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-08-27 · Exercise / conversion · Disposed 26,116 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.12 · Expires 2029-08-07	Direct	0	Reported balance After 2026-08-27 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-08-27 · Exercise / conversion · Disposed 27,584 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

F8: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.

PLIANT THERAPEUTICS, INC.

Report date July 09, 2026 · Filed July 13, 2026

This filing explicitly reported no securities owned.

iTeos Therapeutics, Inc.

Report date June 11, 2024 · Filed June 13, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-06-11	Direct	24,200	Reported balance After 2024-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-11 · Grant · Acquired 24,200 · Balance 24,200

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Jounce Therapeutics, Inc.

Report date May 03, 2023 · Filed May 04, 2023

Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19	Direct	Reported balance After 2023-05-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-05-03 · Disposition to issuer · Disposed 31,400 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.58	Direct	Reported balance After 2023-05-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-03 · Disposition to issuer · Disposed 7,850 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27	Direct	Reported balance After 2023-05-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-05-03 · Disposition to issuer · Disposed 15,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80	Direct	Reported balance After 2023-05-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-05-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2021 Filed Jun 22, 2021 20:47 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	GrantStock Option (Right to Buy) · Derivative	15,700	$0.00 Strike: $7.27	$0.00	Disclosure SEC source: 0001640455-21-000112 · wf-form4_162439483329796.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:24 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	4,560	$0.00 Strike: $26.03	$0.00	Disclosure SEC source: 0000899243-21-025143 · doc4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2031-06-17 F1 · derivative.exercise_date: This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
June 05, 2021 Filed Jun 9, 2021 22:57 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	1,206	$176.47	$212,822.82	Disclosure SEC source: 0001765581-21-000063 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,086 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. Read SEC document
April 29, 2021 Filed May 3, 2021 19:09 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	33,217	$0.00 Strike: $24.11	$0.00	Disclosure SEC source: 0000899243-21-017844 · doc4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,217 shares Expires 2031-04-29 F1 · derivative.exercise_date: This stock option shall vest over 3 years, with 1/3 vesting on April 29, 2022, and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document
March 05, 2021 Filed Mar 10, 2021 00:30 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	741	$164.75	$122,079.75	Disclosure SEC source: 0001765581-21-000036 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,145 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document
February 25, 2021 Filed Mar 1, 2021 22:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	8,535	$0.00	$0.00	Disclosure SEC source: 0001765581-21-000020 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,886 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document
June 26, 2020 Filed Jun 29, 2020 23:32 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	GrantStock Option (Right to Buy) · Derivative	6,775	$0.00 Strike: $7.58	$0.00	Disclosure SEC source: 0001640455-20-000071 · wf-form4_159347353043628.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,775 Underlying: Common Stock · 6,775 shares Expires 2030-06-26 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 26, 2020 Filed Jul 2, 2020 23:35 UTC Amendment	Jounce Therapeutics, Inc. JNCE · Entity 15754	GrantStock Option (Right to Buy) · Derivative	7,850	$0.00 Strike: $7.58	$0.00	Disclosure SEC source: 0001640455-20-000087 · wf-form4a_159373288738507.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires 2030-06-26 F1 · shares: The original Form 4 filed on June 29, 2020 erroneously reported 6,775 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option. F2 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 05, 2020 Filed Jun 6, 2020 01:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	943	$120.65	$113,772.95	Disclosure SEC source: 0001765581-20-000061 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,204 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020. Read SEC document
February 27, 2020 Filed Mar 2, 2020 23:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	26,116	$0.00 Strike: $113.10	$0.00	Disclosure SEC source: 0001765581-20-000020 · edgardoc.xml · derivative · entry 3 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,116 Underlying: Ordinary Shares · 26,116 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document
February 27, 2020 Filed Mar 2, 2020 23:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantIncentive Stock Option (right to buy) · Derivative	884	$0.00 Strike: $113.10	$0.00	Disclosure SEC source: 0001765581-20-000020 · edgardoc.xml · derivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884 Underlying: Ordinary Shares · 884 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document
February 27, 2020 Filed Mar 2, 2020 23:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	10,800	$0.00	$0.00	Disclosure SEC source: 0001765581-20-000020 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document
January 21, 2020 Filed Jan 23, 2020 13:08 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	GrantStock Option (Right to Buy) · Derivative	31,400	$0.00 Strike: $7.19	$0.00	Disclosure SEC source: 0001640455-20-000014 · wf-form4_157978488746415.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2030-01-21 F1 · derivative.exercise_date: The option was granted on January 21, 2020 and will vest in equal quarterly installments during the twelve quarters following the grant date, subject the to Reporting Person's continued service as a director. Read SEC document
August 08, 2019 Filed Aug 12, 2019 20:59 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	27,584	$0.00 Strike: $137.12	$0.00	Disclosure SEC source: 0001765581-19-000056 · edgardoc.xml · derivative · entry 3 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,584 Underlying: Ordinary Shares · 27,584 shares Expires 2029-08-07 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document
August 08, 2019 Filed Aug 12, 2019 20:59 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantIncentive Stock Option (right to buy) · Derivative	2,916	$0.00 Strike: $137.12	$0.00	Disclosure SEC source: 0001765581-19-000056 · edgardoc.xml · derivative · entry 2 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,916 Underlying: Ordinary Shares · 2,916 shares Expires 2029-08-07 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document
August 08, 2019 Filed Aug 12, 2019 20:59 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	12,200	$0.00	$0.00	Disclosure SEC source: 0001765581-19-000056 · edgardoc.xml · nonDerivative · entry 1 Iannone Robert · CIK 0001737329 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,200 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document
March 14, 2019 Filed Mar 18, 2019 16:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	25,660	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0001104659-19-015617 · a4.xml · derivative · entry 2 Iannone Robert · CIK 0001737329 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,660 Underlying: Common Stock, par value $0.01 per share · 25,660 shares Expires 2026-03-14 F2 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant. Read SEC document
March 14, 2019 Filed Mar 18, 2019 16:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	51,230	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0001104659-19-015617 · a4.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,230 Underlying: Common Stock, par value $0.01 per share · 51,230 shares Expires 2026-03-14 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter. Read SEC document
September 14, 2018 Filed Sep 18, 2018 15:06 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	15,900	$0.00 Strike: $22.27	$0.00	Disclosure SEC source: 0001171843-18-006605 · ownership.xml · derivative · entry 1 Iannone Robert · CIK 0001737329 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock, par value $0.01 per share · 15,900 shares Expires 2025-09-14 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and on a quarterly basis thereafter over a three year period. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.